SAN DIEGO , Dec. 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 , at
SAN DIEGO , Dec. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on December 15, 2020 , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 141,975 shares of its common
- Data selected for late-breaker oral presentation on December 14 - Novel mechanism of action evaluated in moderate-to-severe atopic dermatitis (AD) - Significant unmet need exists for a safe, once-daily, oral therapy in AD SAN DIEGO , Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
- Evaluating 2 mg etrasimod in study participants with moderately to severely active ulcerative colitis (UC) - Topline data from ELEVATE UC 12 and UC 52 trials on track for Q1 2022 - Due to the high number of participants currently in screening queue, screening to continue for an additional three
Paul D. Streck , M.D., Appointed as Senior Vice President, Clinical Development and Chief Medical Officer, Bringing Successful Development and Launch Experience Across Multiple Therapeutic Indications SAN DIEGO --(BUSINESS WIRE)--Nov. 30, 2020-- Arena Pharmaceuticals, Inc.
SAN DIEGO , Nov. 24, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Tuesday,
SAN DIEGO , Nov. 19, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on November 15, 2020 , the Compensation Committee of its Board of Directors granted to 13 new employees inducement stock options to purchase an aggregate of 96,025 shares of its common stock
- Etrasimod 2 mg in the primary analysis achieved statistical significance of the registrational endpoint vIGA at week 12 - Etrasimod 2 mg in the primary analysis demonstrated statistical significance in percent change in EASI, EASI-75, and pruritis at week 4 - Etrasimod did not meet the Ph 2b
SAN DIEGO , Oct. 20, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on October 15, 2020 , the Compensation Committee of its Board of Directors granted to seven new employees inducement stock options to purchase an aggregate of 66,475 shares of its common stock